Skip to main content

Christmas appeal

Support Heart-First Science and protect people from stroke

Donate today

Through collaboration with the HRI’s Vascular Complications Group, we continue to study potential therapies to boost TRAIL, a novel mediator with marked anti-inflammatory and anti-atherosclerotic properties, in patients with coronary disease.

This work has resulted in several presentations at international cardiovascular meetings, and two publications.

Support Heart-First Science and protect…

Donate today